of 54.8% with 98.5% specificity in cancers without SoC screening options (excluding lung) and 63.7% in the six most aggressive cancers with the shortest survival rates (esophagus, liver, lung, ovarian, pancreatic, and stomach). Natera presented data from GALAXY arm of the CIRCULATE-Japan trial...
Evaluation of other diseases in which the presence of upper gastro-intestinal (GI) pathological conditions might modify other planned management (e.g., persons who have a history of ulcer or GI bleeding who are scheduled for organ transplantation, long-term anti-coagulation, or long-term non-ste...
Although glycomics has already reached clinical practice in the case of glycoengineered therapeutic proteins or even a diagnostic test (Glyco Liver Profile, Helena Biosciences) [150], some obstacles have to be overcome if wide use of these methods is to be expected in the near future. These bar...